CLINICAL TRIALS AND OBSERVATIONS A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
نویسندگان
چکیده
David S. Siegel,1 Thomas Martin,2 Michael Wang,3 Ravi Vij,4 Andrzej J. Jakubowiak,5 Sagar Lonial,6 Suzanne Trudel,7 Vishal Kukreti,7 Nizar Bahlis,8 Melissa Alsina,9 Asher Chanan-Khan,10 Francis Buadi,11 Frederic J. Reu,12 George Somlo,13 Jeffrey Zonder,14 Kevin Song,15 A. Keith Stewart,16 Edward Stadtmauer,17 Lori Kunkel,18 Sandra Wear,19 Alvin F. Wong,20 Robert Z. Orlowski,3 and Sundar Jagannath21
منابع مشابه
Regular Article CLINICAL TRIALS AND OBSERVATIONS A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma Paul G. Richardson, Wanling Xie, Sundar Jagannath, Andrzej Jakubowiak, Sagar Lonial, Noopur S. Raje, Melissa Alsina, Irene M. Ghobrial, Robert L. Schlossman, Nikhil C. Munshi, Amitabha Mazumder, David H. Vesole, Jonathan L. Kaufman, Kathleen Colson, Mary McKenney, Laura E. Lu...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
1Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine and Cancer Institute, Pittsburgh, PA; 2Myeloma Program, Karmanos Cancer Institute, Detroit, MI; 3University of Pittsburgh Medical Center Cancer Centers, Pittsburgh, PA; 4Biostatistics Facility, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA; and 5College of ...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma
Bortezomib, a proteasome inhibitor with efficacy in multiple myeloma, is associated with thrombocytopenia, the cause and kinetics of which are different from those of standard cytotoxic agents. We assessed the frequency, kinetics, and mechanism of thrombocytopenia following treatment with bortezomib 1.3 mg/m2 in 228 patients with relapsed and/or refractory myeloma in 2 phase 2 trials. The mean ...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma
Bortezomib, a potent and reversible proteasome inhibitor, affects the myeloma cell and its microenvironment, resulting in downregulation of growth and survival signaling pathways and durable responses in patients with relapsed and refractory myeloma. Potential associations between baseline parameters and outcomes with bortezomib were explored in 202 patients who received bortezomib 1.3 mg/m2 tw...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)
1Department of Internal Medicine II, Division of Hematology and Medical Oncology, University Hospital Wuerzburg and Early Clinical Development Unit of Comprehensive Cancer Center Mainfranken (CCCM), Wuerzburg; 2Department of Hematology/Oncology, HELIOS Klinikum Berlin Buch, Berlin; 3Department of Internal Medicine III, University Hospital, Ulm; 4Medizinische Klinik und Poliklinik I, Universität...
متن کامل